Answers are grounded in this paper and cite their sources.
Immunotherapy using dendritic cells has emerged as a potent option for the treatment of the solid tumours. Over the past few decades, multiple clinical trials have been carried with the aim of increasing the efficacy of this therapy. Many protocols have been developed to generate large scale production of dendritic cell which have been used in clinical trials. Dendritic cell therapy has demonstrated high overall response rates, resulting in tumor regression and prolonged survival. Various factors, viz., number of dendritic cell administration, antigen source, mode of administration, combination strategy are still under clinical development. This review summarizes the results of clinical trials for multiple solid malignancies. As a sole review for oncologist, it can help improve understanding of the subject matter, with the aim of increasing the participation of patients at earlier stages of malignancies to participate in clinical trials or treatment plans using dendritic cell immunotherapy.
No takes yet. Share an insight, caveat, or question.
Luis Martínez (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: